Cardiopulmonary involvement in Fabry's disease

Acta Cardiologica

Volumn 65, Issue 2, 2010, Pages 185-192

  Koskenvuo, Juha W ^a,b   Kantola, Ilkka M ^a   Nuutila, Pirjo ^a,b   Knuuti, Juhani ^b   Parkkola, Riitta ^a   Mononen, Ilkka ^a   Hurme, Saija ^b   Kalliokoski, Riikka ^b   Viikari, Jorma S ^a   Wendelin Saarenhovi, Maria ^a,b   Kiviniemi, Tuomas O ^a   Hartiala, Jaakko J ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Cardiopulmonary involvement; Diffusing capacity; Fabry's disease; HRCT; MRI; Spirometry; Symptoms

Indexed keywords

AGALSIDASE BETA; AMITRIPTYLINE; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; COCODAMOL;

ADULT; AEROBIC EXERCISE; AGED; ARTICLE; BICYCLE ERGOMETRY; CARDIOPULMONARY FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME REPLACEMENT; EXERCISE TEST; FABRY DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; QRS COMPLEX; SELF REPORT; SEX RATIO; SPIROMETRY; VITAL CAPACITY;

ADULT; AGED; ALPHA-GALACTOSIDASE; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FABRY DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LUNG; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 77951525736     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.65.2.2047052     Document Type: Article

References (36)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-254
2. Schafer E, Baron K, Widmer U, Deegan P, Neumann HP, Sunder-Plassmann G, Johansson JO, Whybra C, Ries M, Pastores GM, Mehta A, Beck M, Gal A. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 2005; 25: 412.
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-775 (Pubitemid 33032933)
4. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-38. (Pubitemid 34218568)
5. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 1976; 54: 818-825
6. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986; 7: 1157-1161 (Pubitemid 16103117)
7. Pochis WT, Litzow JT, King BG, Kenny D. Electrophysiologic findings in Fabry's disease with a short PR interval. Am J Cardiol 1994; 74: 203-204 (Pubitemid 24219320)
8. Kariman K, Singletary WV, Jr, Sieker HO. Pulmonary involvement in Fabry's disease. Am J Med 1978; 64: 911-912
9. Rosenberg DM, Ferrans VJ, Fulmer JD, Line BR, Barranger JA, Brady RO, Crystal RG. Chronic airflow obstruction in Fabry's disease. Am J Med 1980; 68: 898-905.
10. Bierer G, Balfe D, Wilcox WR, Mosenifar Z. Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2006; 29: 572-579 (Pubitemid 44193273)
11. Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schilero G, Eng CM, Desnick RJ. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 1997; 155: 1004-1010 (Pubitemid 27133416)
12. Desnick RJ, Ioannou YA, Eng ME. alfa-Galactosidase a deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly D, Valle D, editors. The metabolic and molecular bases of inherited disease. New York, McGraw-Hill, 2001: p. 3733-3774
13. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236-242 (Pubitemid 38406640)
14. Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E, Penttinen M, Knuuti J, Mononen I, Kantola IM. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 2008; 31: 432-441
15. Viljanen AA, Viljanen BC, Halttunen PK, Kreus KE. Pulmonary diffusing capacity and volumes in healthy adults measured with the single breath technique. Scand J Clin Lab Invest Suppl 1982; 159: 21-34.
16. Arstila M, Impivaara O, Mäki J. New ergometric reference values for clinical exercise tests. Scand J Clin Lab Invest 1990; 50: 747-755 (Pubitemid 20369262)
17. Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kampmann R, Whybra C, Miebach E, Beck M. Electrocardiographic signs of hypertrophy in Fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 2002; 91: 21-27
18. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol 2007; 40: 228-234
19. Macfarlane PW, McLaughlin SC, Devine B, Yang TF. Effects of age, sex, and race on ECG interval measurements. J Electrocardiol 1994; 27 Suppl: 14-19
20. Chen CY, Chiang BN, Macfarlane PW. Normal limits of the electrocardiogram in a Chinese population. J Electrocardiol 1989; 22: 1-15.
21. Schettini C, Bianchi M, Nieto F, Sandoya E, Senra H. Ambulatory blood pressure: normality and comparison with other measurements. Hypertension Working Group. Hypertension 1999; 34: 818-825
22. Michelsen S, Knutsen KM, Stugaard M, Otterstad JE. Is left ventricular mass in apparently healthy, normotensive men correlated to maximal blood pressure during exercise? Eur Heart J 1990; 11: 241-248
23. Koskenvuo JW, Karra H, Lehtinen J, Niemi P, Pärkkä J, Knuuti J, Hartiala JJ. Cardiac MRI: accuracy of simultaneous measurement of left and right ventricular parameters using three different sequences. Clin Physiol Funct Imaging 2007; 27: 385-393 (Pubitemid 47604424)
24. Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging 2003; 17: 323-329 (Pubitemid 36259246)
25. Magage S, Lubanda JC, Susa Z, Bultas J, Karetova D, Dobrovolny R, Hrebicek M, Germain DP, Linhart A. Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis 2007; 30: 790-799 (Pubitemid 47559892)
26. Bierer G, Kamangar N, Balfe D, Wilcox WR, Mosenifar Z. Cardiopulmonary exercise testing in Fabry disease. Respiration 2005; 72: 504-511 (Pubitemid 41433566)
27. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96: 842-846 (Pubitemid 41319722)
28. Sheth KJ, Thomas JP,Jr. Electrocardiograms in Fabry's disease. J Electrocardiol 1982; 15: 153-156
29. Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 2003; 63: 46-52. (Pubitemid 36949894)
30. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324: 395-399
31. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, Ledvinova J, Belohlavek, Kral V, Dorazilova V. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990; 417: 449-455 (Pubitemid 20345820)
32. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D, Zeman J, Ledvinova J, Poupetova H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139: 1101-8. (Pubitemid 30390343)
33. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
34. Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, Beck M, Ramaswami U, Linhart A, Gal A, Houge G, Widmer U, Mehta A, Sunder-Plassmann G. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 2006; 19: 782-787 (Pubitemid 44107697)
35. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004; 34: 838-844 (Pubitemid 39657931)
36. Piirilä P, Lindqvist A, Rytilä P, Välimäki P, Sovijärvi ARA. Which reference values should be applied to people with different ethnical backgrounds? [in Finnish]. Suom Lääkäril 2001; 56: 4487-4492